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Abstract
Introduction: The aim of this study was to evaluate the effects of polycystic ovary syndrome (PCOS) and body mass index (BMI) on serum 
adropin and ischemia modified albumin (IMA) levels.
Material and methods: This prospective cross-sectional study was performed with a total of 120 women [group1; non-PCOS = 60 (BMI 
< 25 = 30, BMI ≥ 25 = 30) and group 2; PCOS = 60 (BMI < 25 = 30, BMI ≥ 25 = 30)]. Blood samples were collected between the third and 
fifth days of the women’s menstrual cycles after a night of fasting.
Results: There were no differences between the groups in relation to age, basal follicle stimulating hormone, estradiol, thyroid stimulating 
hormone, prolactin, high-density lipoprotein cholesterol, total testosterone, dehydroepiandrosterone sulfate levels, systolic and diastolic 
blood pressures. A significant difference was found in basal luteinizing hormone, fasting glucose, insulin, homeostatic model assessment 
of insulin resistance, total cholesterol, low-density lipoprotein cholesterol, triglycerides, free testosterone levels, waist-to-hip ratios and the 
Ferriman-Gallwey scores between the PCOS and non-PCOS patients in the lean and overweight groups (P < 0.05). The serum adropin 
levels in the lean PCOS group were lower than in the lean non-PCOS group (P < 0.05) and were lower in the overweight PCOS group 
than in the overweight non-PCOS group (P < 0.05). There was also a statistically significant difference in serum IMA levels in the PCOS 
group than in the non-PCOS group in both the lean and overweight groups (P < 0.05). 
Conclusions: Although serum adropin levels were significantly decreased in the PCOS group, IMA levels increased. Further studies are 
needed to determine the effects of adropin and IMA in women with PCOS and to use a new marker to monitorize treatment outcomes. 
(Endokrynol Pol 2018; 69 (2): 135–141)
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Streszczenie 
Wstęp: Badanie przeprowadzono w celu oceny wpływu zespołu policystycznych jajników (polycystic ovary syndrome, PCOS) i wskaźnika 
masy ciała (body mass index, BMI) na surowicze stężenia adropiny i albumin modyfikowanej niedokrwieniem (ischemia modified albumin, IMA).
Materiał i metody: To prospektywne badanie przekrojowe obejmowało 120 kobiet [grupa 1: osoby bez PCOS — n= 60 (BMI < 25 — 
n= 30; BMI ≥ 25 — n = 30) oraz grupa 2: osoby z PCOS — n= 60 (BMI < 25 — n= 30, BMI ≥ 25 —n = 30)]. Próbki krwi pobierano między 
trzecim a piątym dniem cyklu menstruacyjnego badanych kobiet, rano na czczo.
Wyniki: Grupy nie różniły się pod względem wieku, podstawowego stężenia hormonu folikulotropowego, stężeń estradiolu, tyreotropiny, 
prolaktyny, cholesterol frakcji HDL, testosteronu całkowitego i siarczanu dehydroepiandrosteronu ani skurczowego i rozkurczowego 
ciśnienia tętniczego. Stwierdzono natomiast istotne różnice między grupą z PCOS i bez PCOS w podgrupach osób szczupłych i otyłych 
w zakresie podstawowego stężenia hormonu luteinizującego, glikemii na czczo, wskaźnika insulinooporności w modelu homeostazy, 
stężeń cholesterolu całkowitego, cholesterolu frakcji LDL, triglicerydów i wolnego testosteronu, a także wskaźnika talia-biodra oraz oceny 
w skali Ferrimana-Gallweya (P < 0,05). Stężenia adropiny w osoczu były niższe w grupie szczupłych kobiet z PCOS niż u szczupłych osób 
niechorujących na PCOS (P < 0,05) oraz były niższe u otyłych osób z PCOS niż u otyłych osób z grupy bez PCOS (P < 0,05). Stwierdzono 
również statystycznie istotną różnice w stężeniach IMA w surowicy między kobietami z PCOS i bez PCOS, zarówno w podgrupie osób 
szczupłych, jak i otyłych (P < 0,05). 
Wnioski: Mimo że surowicze stężenia adropiny były istotnie niższe w grupie z PCOS, stężenia IMA były podwyższone w tej grupie 
badanych. Konieczne są dalsze badania w celu określenia wpływu adropiny i IMA u kobiet z PCOS i stosowanie nowych wskaźników 
do monitorowania efektów leczenia. (Endokrynol Pol 2018; 69 (2): 135–141)
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Introduction
Polycystic ovary syndrome (PCOS), which can cause 
hormonal, metabolic, and reproductive anomalies 
and is seen in 5–10% of women of reproductive age, is 
a chronic inflammatory endocrinopathy [1]. The etiol-
ogy of PCOS, a complex heterogeneous disease thought 
to play a role in genetic and environmental factors, is 
not fully understood. Basic features of PCOS include 
ovulatory dysfunction, biochemical and clinical hy-
perandrogenism, and polycystic ovary appearance on 
ultrasonography (USG) [1, 2]. Defensive steroid biosyn-
thesis and hyperinsulinemia associated with obesity-
independent insulin resistance (IR) may increase the hy-
perandrogenism findings [2]. PCOS is associated with 
an increased risk of type 2 diabetes mellitus (DM) and 
cardiovascular disease due to atherosclerosis, metabolic 
syndrome, hyperlipidemia, hypertension, obesity, and 
oxidative stress. PCOS is also associated with infertility 
due to decreased oocyte maturation, fertilization, em-
bryogenesis and miscarriage, preeclampsia, diabetes-
related congenital abnormalities [3–6].
Adropin, which was discovered for the first time 
in 2008 by Kumar et al. [7], is a product of the energy 
homeostasis-associated (Enho) gene and a peptide-
structured hormone containing 42 aminoacid, and 
is thought to play a role in the regulation of energy 
homeostasis and endothelial function [3, 7–10]. Lower 
adropin levels are associated with IR independent of 
obesity, dyslipidemia, hepatic steatosis, and increased 
fat mass. Overexpression or exogenous administration 
improves glucose homeostasis and increases blood 
flow and capillary density in rodents; it also has an 
endothelial protective role by increasing eNOS expres-
sion [7, 11]. Circulating adropin levels were found to 
be low in DM, gestational DM, metabolic syndrome, 
non-alcoholic fatty liver disease, PCOS, and coronary 
artery disease [5, 9, 10, 12, 13].
It has been reported that a change of N terminal 
structure of albumin occurs in cases of ischemic states in 
the human body, and a new molecule named ischemia-
modified albumin (IMA), which cannot bind metal 
ions, is created [6, 14]. Higher IMA levels are observed 
more often in cases of myocardial ischemia, but can also 
increase in cases of type 2 DM, pulmonary embolism, 
liver cirrhosis, metabolic syndrome, and intrauterine 
pathologies [14, 15]. To our knowledge, serum IMA 
levels in patients with PCOS are in conflict with the 
literature. In addition to a study revealing that serum 
IMA levels did not change in patients with PCOS [16], 
other studies have shown that higher serum IMA levels 
are increasingly common [6, 17, 18].
In the current study, our aim was to investigate se-
rum levels of adropin and IMA in women with PCOS.
Material and methods
A prospective sequential cross-sectional study was 
performed with a total of 120 women between January 
and December 2016 at the department of obstetric and 
gynecology, Konya Research and Education Hospital. 
Sixty PCOS patients and 60 age-and-BMI-matched 
non-PCOS patients with normal menstrual cycles were 
consecutively included. Clinical and demographic 
characteristics of all patients were evaluated by a single 
investigator. One hundred and twenty blood samples 
were analyzed. Patients were divided into subgroups 
according to BMI (BMI < 25 was considered lean and 
BMI ≥ 25 was considered overweight). This study was 
approved by the local ethics committee and the insti-
tutional review board.
Written and oral informed consent was obtained 
from all volunteers. The ethical principles for medi-
cal research involving human subjects stipulated in 
the 18th World Medical Association Declaration of 
Helsinki were applied. The BMI values and hormonal, 
biochemical, and ultrasonographic parameters were 
recorded. Sixty women (BMI < 25 = 30, BMI ≥ 25 = 30) 
were diagnosed with PCOS according to the menstrual, 
laboratory, and ultrasonographic criteria defined by 
a consensus workshop sponsored by ESHRE/ASRM in 
Rotterdam in May 2003 [19]. It includes: i = menstrual 
disorders oligoovulation/anovulation); ii = clinical and/
or biochemical evidence of hyperandrogenism; and iii 
= polycystic ovaries on ultrasound examination (at least 
10 follicles 2–9 mm in size or the volume of the ovary 
greater than 10 mL). Sixty non-PCOS women [(BMI < 
25 = 30, BMI ≥ 25 = 30)] were evaluated as the control 
group. The Ferriman-Gallwey (FG) method was used 
to determine hirsutism [20]. Subjects were accepted as 
hirsute if their FG scores were ≥ 8. Biochemical hyper-
androgenism was defined as an increase in the serum 
concentrations of free testosterone (normal values: 
0.46–2.48 pg/dL) and/or total testosterone (normal 
values 0.15–0.7 ng/mL), according to manufacturer’s 
instructions. 
Control subjects were included from healthy 
women who visited the gynecology clinic for routine 
gynecological examination. The women in the control 
group had regular menstrual cycles (28–32 days) and 
no concomitant health problems or signs of hyperan-
drogenism.
The exclusion criteria were age < 18 or > 35 years, 
BMI ≥ 35 kg/m2, evidence of clinical hyperandro-
genemia (Cushing’s syndrome, hyperprolactinemia, 
congenital adrenal hyperplasia, diseases of the adrenal 
gland,thyroid disorders, galactorrhea, breastfeeding, 
and pregnancy); type 1/type 2 diabetes; hypertension; 
active or chronic liver or renal failure, a history of coro-
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nary artery disease; acute infection (within 14 days); the 
presence of any chronic inflammatory orautoimmune 
disease; known malignancy; hormonal contraception 
and/or anti-androgen therapy (within 6 months); and 
tobacco or alcohol use.
Study protocol
Anthropometric measurements including weight, 
height, and waist-to-hip ratio were peformed follow-
ing detailed anamnesis and physical and gynecological 
examinations. Measurements of height and weight 
were performed with the subjects in light clothing. The 
BMI was calculated using the weight by the square of 
the height (weight/height2–kg/m2). Waist circumference 
(cm) was measured midway between the lower rib 
margin and the iliac crest at the level of the umbilicus 
during expiration. Hip circumference was calculated at 
the widest circumference at the level of the buttocks, 
and the waist-to-hip ratio (WHR) was calculated to 
assess body-fat distribution. Blood pressure was meas-
ured in the sitting position after a rest period of at least 
5 minutes. IR was calculated using homeostatic model 
assessment of insulin resistance (HOMA-IR) and was 
calculated according to the following formula: fasting 
insulin (µIU/mL) x fasting glucose (mmol/L)/22.5) [21].
Biochemical evaluation
Venous blood samples were collected from the ante-
cubital veins of all subjects from 8:00 a.m. and 10:00 
a.m., between the third and fifth days of the menstrual 
cycle after a night of fasting. The plasma samples were 
stored at –80°C for adropin and IMA analysis. Thyroid 
stimulating hormone (TSH), prolactin, follicle stimulat-
ing hormone (FSH), luteinizing hormone (LH), estradiol 
(E2), fasting blood glucose (FBG), serum insulin, hs-CRP, 
total cholesterol, triglycerides (TG), high-density lipo-
protein cholesterol (HDL-C), low-density lipoprotein 
cholesterol (LDL-C), free testosterone, total testos-
terone, dehydroepiandrosterone sulfate (DHEA-S), 
adropin, and IMA levels were measured on the day 
of sampling. 
Serum FBG, hs-CRP, total cholesterol, HDL-C, LDL-
C, and TG levels were measured by commercially avail-
able kits based on routine methods on the Olympus AU 
5800 auto-analyzer (Beckman Coulter Inc., Fullerton, 
CA, USA).
Serum TSH, PRL, FSH, LH, testosterone, and E2 
levels were measured by Advia Centaw XP systems 
(Siemens Healthcare Diagnostics, Germany). Serum 
free testosterone was measured by Radio Immune As-
say method (LB 2111 Multi Crystal Gamma Counter- 
Berthold, Germany). 
Serum insulin and DHEA-S levels (NR:6-27mIU/mL) 
were measured by Immulite 2000 with the chemilumi-
nescence immunometric method (Siemens Healthcare 
Diagnostics). The analytic sensitivity of the assay was 
2 mlU/mL. Intra-assay variations as coeefficients of 
variation (CVs) for various insulin values were 5.5% 
(7.67 mlU/mL), 4.0% (12.5 mlU/mL), 3.3% (17.2 mlU/
mL), 3.9% (26.4 mlU/mL), 3.8% (100 mlU/mL), and 3.7% 
(291 mlU/mL). Interassay variations for the insulin 
concentrations mentioned above were 7.3%, 4.9%, 4.1%, 
5%, 4.2%, and 5.3%, respectively.
Serum adropin concentrations were measured by an 
enzyme-linked immunosorbent assay kit (Catalog No. 
201-12-3107 Sunred Biological Technology Co., Shang-
hai, PRC) as recommended by the manufacturer ’s 
protocol. CVs for intra-assay were < 9%; CVs for inter 
assay were < 11%; sensitivity was 4,735 pg/mL; and 
assay range was 5–1000 pg/mL.
Serum IMA concentrations were measured by an 
enzyme-linked immunosorbent assay kit (Catalog No. 
201-12-1173 Sunred Biological Technology Co., Shang-
hai, PRC) as recommended by the manufacturer ’s 
protocol. Sensitivity was 2,226 ng/mL; assay range was 
3–600 ng/mL. 
Statistical analysis
We used the SPSS 15 (Statistical Package for Social 
Sciences, SPSS Inc) software for statistical analyses. 
The distributions of all of the continuous variables for 
normal or abnormal distributions were tested using 
Shapiro-Wilk test. The homogenity of variances was 
evaluated using the Levene Test. Metric discrete and 
continuous variables are expressed as the mean ± SD, 
where applicable. Nominal data were expressed as the 
number of cases and percentages. Though the normal 
distributed variables between groups were compared 
using Student’s t test, the Mann-Whitney U test was 
applied to the abnormal distributed variables. Nomi-
nal data were analyzed using Pearson’s Chi square or 
Fisher’s exact test, when appropriate. A p value < 0.05 
was considered statistically significant. However, for all 
multiple comparisons, the Bonferroni adjustment was 
applied to control for Type I error.
Results
Table I describes demographic and clinical characteris-
tics in patients based on PCO and BMI. No statistically 
significant differences were found between the groups 
in relation to age, basal FSH and estradiol, HDL-C, 
total testosterone, and DHEA-S, TSH, prolactin levels, 
systolic and diastolic blood pressures. There was a sig-
nificant difference in basal LH, fasting glucose, insulin, 
HOMA-IR, total cholesterol, LDL-C, triglyceride, and 
free testosterone levels, waist-to-hip ratio and FG score 
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Table I. Demographic and clinical characteristics in patients based on PCO and BMI 
Tabela I. Demograficzna i kliniczna charakterystyka chorych w zależności od występowania zespołu policystycznych jajników 







*BMI < 25 kg/m2 25.30 ± 5.59 25.91 ± 4.60 0.644
**BMI ≥ 25 kg/m2 26.97 ± 5.24 27.22 ± 4.52 0.845
p-valueb 0.238 0.274
TSH [µIU/mL]
*BMI < 25 kg/m2 2.19 ± 1.20 1.72 ± 1.10 0.123
**BMI ≥ 25 kg/m2 1.83 ± 1.08 1.32 ± 0.95 0.057
p-valueb 0.227 0.133
Prolactin [ng/mL]
*BMI < 25 kg/m2 11.32 ± 8.60 14.32 ± 7.47 0.155
**BMI ≥ 25 kg/m2 12.56 ± 6.81 15.50 ± 8.06 0.132
p-valueb 0.539 0.559
Basal FSH [IU/L]
*BMI < 25 kg/m2 6.78 ± 1.65 7.24 ± 0.92 0.197
**BMI ≥ 25 kg/m2 6.85 ± 1.40 7.42 ± 1.19 0.096
p-valueb 0.878 0.514
Basal LH [IU/L]
*BMI < 25 kg/m2 6.08 ± 1.86 10.61 ± 5.79 < 0.001
**BMI ≥ 25 kg/m2 6.28 ± 1.58 11.47 ± 6.57 < 0.001
p-valueb 0.672 0.592
Basal E2 [pg/mL]
*BMI < 25 kg/m2 56.04 ± 16.62 51.02 ± 11.70 0.181
**BMI ≥ 25 kg/m2 52.38 ± 6.43 49.37 ± 14.10 0.295
p-valueb 0.268 0.626
Waist to hip ratio
*BMI < 25 kg/m2 0.74 ± 0.11 0.82 ± 0.09 0.005
**BMI ≥ 25 kg/m2 0.79 ± 0.10 0.92 ± 0.12 < 0.001
p-valueb 0.125 0.001
SBP [mmHg]
*BMI < 25 kg/m2 105.00 ± 10.74 109.00 ± 9.94 0.140
**BMI ≥ 25 kg/m2 102.00 ± 10.30 106.67 ± 9.22 0.070
p-valueb 0.274 0.351
DBP [mmHg]
*BMI < 25 kg/m2 66.00 ± 7.70 68.68 ± 5.07 0.119
**BMI ≥ 25 kg/m2 68.33 ± 8.33 71.17 ± 7.84 0.181
p-valueb 0.265 0.149
Ferriman-Gallwey score
*BMI < 25 kg/m2 5.83 ± 1.05 15.90 ± 6.55 < 0.001
**BMI ≥ 25 kg/m2 6.361.58 16.63 ± 6.94 < 0.001
p-valueb 0.131 0.676
Fasting glucose 
*BMI < 25 kg/m2 75.10 ± 12.81 82.971 ± 1.63 0.016








*BMI < 25 kg/m2 5.80 ± 5.04 12.68 ± 8.07 < 0.001
**BMI ≥ 25 kg/m2 6.87 ± 3.94 15.89 ± 13.37 < 0.001
p-valueb 0.361 0.271
HOMA-IR [mg/dL]
*BMI < 25 kg/m2 1.11 ± 1.08 2.70 ± 1.89 < 0.001
**BMI ≥ 25 kg/m2 1.39 ± 0.72 3.43 ± 3.19 0.002
p-valueb 0.361 0.271
Insulin resistance [%]
*BMI < 25 kg/m2 3 (10%) 12 (40%) 0.015
**BMI ≥ 25 kg/m2 9 (30%) 21 (70%) 0.004
p-valueb 0.104 0.037
LDL-C [mg/dL] 
*BMI < 25 kg/m2 109.03 ± 27.37 125.50 ± 27.06 0.023
**BMI > 25 kg/m2 114.70 ± 25.89 135.50 ± 35.10 0.011
p-valueb 0.414 0.221
HDL-C [mg/dL]
*BMI < 25 kg/m2 51.57 ± 10.30 49.54 ± 10.22 0.455
**BMI > 25 kg/m2 47.77 ± 9.82 45.27 ± 9.28 0.434
p-valueb 0.149 0.246
Trigycerides [mg/dL]
*BMI < 25 kg/m2 85.90 ± 20.93 126.27 ± 26.03 < 0.001
**BMI > 25 kg/m2 93.01 ± 26.89 136.17 ± 24.77 < 0.001
p-valueb 0.259 0.137
hs-CRP [mg/dL]
*BMI < 25 kg/m2 1.86 ± 1.81 3.22 ± 2.78 0.021
**BMI > 25 kg/m2 2.11 ± 1.55 3.89 ± 2.90 0.016
p-valueb 0.703 0.364
Total testosterone [ng/mL]
*BMI < 25 kg/m2 0.37 ± 0.13 0.41 ± 0.15 0.309
**BMI > 25 kg/m2 0.38 ± 0.12 0.43 ± 0.11 0.102
p-valueb 0.813 0.551
Free testosterone [pg/dL]
*BMI < 25 kg/m2 1.15 ± 0.36 2.33 ± 0.56 < 0.001
**BMI > 25 kg/m2 1.35 ± 0.57 2.55 ± 0.62  < 0.001
p-valueb 0.117 0.173
DHEA-SO4 [µg/dL]
*BMI < 25 kg/m2 191.08 ± 97.98 228.88 ± 99.74 0.148
**BMI > 25 kg/m2 206.98 ± 69.88 245.63 ± 102.48 0.094
p-valueb 0.472 0.527
BMI — body mass index; TSH — thyroid stimulating hormone; FSH — follicle-stimulating hormone; LH —luteinizing hormone; E2 — estradiol; HOMA-IR — 
homeostasis model assessment of insulin resistance; LDL-C — low density lipoprotein cholesterol; HDL-C — high density lipoprotein cholesterol; hs-CRP — high 
sensitivity C-reactive protein; DHEA-S — dehydroepiandrosterone sulfate; *BMI < 25kg/m2 and Non-PCOS n = 30; BMI < 25kg/m2 and PCOS n = 30
** BMI ≥ 25 kg/m2 and Non-PCOS n = 30, BMI ≥ 25 kg/m2 and PCOS n = 30; a: Comparisons of PCOS and non-PCOS groups. P < 0.025 set as statistically significant 
(Bonferroni adjustment was applied for controlling Type I error). b: Comparisons of BMI groups p < 0.025 set as statistically significant
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and overweight groups (P < 0.05). Serum adropin and 
IMA levels, based on BMI and PCOS, are presented in 
Table II. We detected lower serum adropin levels in the 
lean PCOS group than in the lean non-PCOS group 
(P < 0.05) and in the overweight PCOS group than in the 
overweight non-PCOS group (P < 0.05). We also noted 
that there was a statistically significant difference in serum 
IMA levels in the PCOS group than in the non-PCOS 
group, in both the lean and overweight groups (P < 0.05). 
Discussion
In the present study, we sought to compare the impact 
of PCOS and BMI on serum adropin and IMA levels in 
patients with PCOS. In the PCOS group, although se-
rum adropin levels were lower in lean and overweight 
patients with PCOS, serum IMA levels were higher than 
those in non-PCOS women. 
The etiopathogenesis of PCOS is not fully known; 
some genetic and environmental conditions are responsi-
ble. It is estimated that IR plays the most important role in 
PCOS. In 70% of cases, PCOS can develop independently 
of obesity; this leads to an increase in androgen produc-
tion, leading to menstrual disorders, polycystic ovary ap-
pearance, and hirsutism [2, 4, 13]. It is also suggested that 
IR causes glucose intolerance, type 2 DM, hypertension, 
dyslipidemia, and cardiovascular diseases [3–6, 22]. In 
addition, it is believed that visceral obesity, which is be-
lieved to be caused by IR, increases the incidence of DM 
and cardiovascular disease in patients with PCOS [5, 17]. 
Because of such conditions, PCOS is now regarded as a 
complex endocrinological disorder, not as a gynecological 
disease. While the IR should ideally be assessed using 
the clamp technique, the HOMA-IR method, which is 
less invasive, is preferred by clinicians. If the HOMA-IR 
value is above 2.5 mg/dL, IR is considered [21]. IR was 
found to be 64% in a study [23] involving 271 PCOS pa-
tients, 30% in lean PCOS cases, and 95% in obese PCOS 
cases in another study [13]. In our study, IR was found 
in 40% of the lean PCOS cases and 70% of the obese 
PCOS cases, compatible with the literature. It has been 
reported that oxidative stress, chronic inflammation, and 
ischemia may cause endothelial dysfunction and increase 
cardiovascular and metabolic complications in patients 
with PCOS [7, 11, 17].
In one study, WHR was shown to be increased in 
obese PCOS patients compared to lean PCOS patients 
and the control group [24]. In another study, no sig-
nificant differences were found [17]. In our study, we 
observed that WHR increases in obese PCOS cases 
compared to lean PCOS cases and the control group, 
which is similar to the results in the first study.
There are many studies in the literature research-
ing the relationship between PCOS and inflammatory 
markers, including hs-CRP. In addition to studies show-
ing that hs-CRP increases in patients with PCOS [25, 26], 
studies show that this has not changed [17, 27, 28]. We 
also found that hs-CRP levels were higher in women 
with PCOS than in the control group. Higher hs-CRP 
levels in PCOS patients show that PCOS is a chronic 
inflammatory disease.
It has been shown that adropin, which is expressed 
in the central nervous system, liver, heart, and skeletal 
muscles, is thought to play a role in energy homeostasis; 
it has also been shown to reduce diets or genetically 
induced obesity in mice. Additionally, systemic admin-
istration or transgenic overexpression reduces IR and 
hepatosteatosis, and regulates glucose homeostasis [3, 7]. 
Adropin deficiency has led to increased fat mass and 
improved IR in mice [29]. In addition, adropin plays 
a role in glucose oxidation, activating pyruvate de-
hydrogenase and lipid oxidation inhibiting carnitine 
palmitoyl transferase [11]. Another study showed that 
intraperitoneal adropin administration in type 2 diabet-
ic rats reduced fasting glucose levels, HOMA-IR, triglyc-
erides, and HbA1c, and increased HDL levels [30]. From 
the aforementioned results, it can be concluded that 
adropin has a protective role against hepatosteatosis, 
hyperinsulinemia, and dyslipidemia. In addition, adro-
pin has a protective effect on andothelial functions by 
increasing nitric-oxide release and activating eNOS [3]. 
Therefore, we think that adropin can be used as a po-
tential biomarker to anticipate IR.
Table II. Adropin and IMA levels based on BMI and PCOS
Tabela II. Stężenia adropiny i albuminy modyfikowanej 
niedokwieniem (ischemia modified albumin, IMA) 
w zależności od występowania zespołu policystycznych 
jajników (polycystic ovary syndrome, PCOS) i wartości 
wskaźnika masy ciała (body mass index, BMI)
Variables Non-PCOS PCOS p-valuea
Adropin levels  
[ng/mL]
*BMI < 25 kg/m2 479.47 ± 358.18 282.20 ± 85.22 0.006
**BMI ≥ 25 kg/m2 390.70 ± 259.25 254.67 ± 71.18 0.009
p-valueb 0.276 0.180
IMA levels [ng/mL]
*BMI < 25 kg/m2 182.03 ± 105.76 294.47 ± 221.21 0.016
**BMI ≥ 25 kg/m2 224.93 ± 101.91 352.60 ± 228.31 0.008
p-valueb 0.115 0.321
BMI — body mass index; IMA — ischemia-modified albumin
*BMI < 25 kg/m2 and Non-PCOS n = 30; BMI < 25 kg/m2 and PCOS n = 30
** BMI ≥ 25 kg/m2 and Non-PCOS n = 30, BMI ≥ 25 kg/m2 and PCOS n = 30
a: Comparisons of PCOS and non-PCOS groups. P < 0.025 set as statistically 
significant (Bonferroni adjustment was applied for controlling Type I error). b: 
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It has been shown that circulating adropin levels 
decreases in GDM, type 2 DM, metabolic syndrome, 
coronary artery disease, nonalcoholic fatty liver disease, 
and PCOS. Either adropin levels decreaseas a result 
of these disorders or lower adropin levels cause these 
diseases; this situation has not been fully clarified [5, 
9, 10]. We also found in our study that, similar to the 
literature results [5, 9, 13], the circulating adropin levels 
in PCOS patients were statistically significantly lower 
than in the control group.
IMA, a marker of oxidative stress, is considered an 
indicator of ischemia and chronic hypoxia situation [6]. 
Chronic hypoxia and oxidative stress may play signifi-
cant roles in PCOS due to IR [6, 17, 18]. IMA is a marker 
often studied in cardiac disorders and has been sug-
gested to be a useful marker in cases of acute coronary 
syndrome and ischemic stroke [6, 15]. Several studies 
in the literature research serum IMA levels in patients 
with PCOS. Although some of them reported higher 
IMA levels [6, 10], others found no significant differ-
ence between PCOS patients and controls [16, 17]. In 
the present study, we found higher serum IMA levels in 
PCOS patients than in the control group. These higher 
IMA concentrations may be in accordance with higher 
triglyceride and low-density lipoprotein cholesterol 
levels. 
The strengths of our study are that none of the 
cases in the PCOS and control groups included in the 
study had received any medical treatment that could 
affect the outcome of the study, and both groups were 
completely homegenous.
A potential weakness of our study is that we could 
not evaluate the visceral fat mass because the necessary 
method was costly, and the measurement technique 
was based on ionizing radiation. Another weakness 
of the current study was that HOMA-IR was used for 
IR instead of the gold standard method, the clamp 
technique. 
In conclusion, we found that although circulating 
adropin levels decreased in women with PCOS, serum 
IMA levels were elevated at the end of our study. Future 
studies are warranted to clarify the effects of adropin 
and IMA in metabolic disorders such as PCOS. We 
believe that the results of our study will shed light on 
future work. 
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